The involvement of human respiratory microbiota in the occurrence and development of major respiratory diseases has been a focus of attention in recent years. The infection of pathogenic microorganisms in respiratory diseases leads to imbalance of respiratory microbiota, but the causal relationship between microbiota and the disease is often unknown, and the mechanism of microbiota host interaction remains to be elucidated. Chronic obstructive pulmonary disease (COPD) is an important chronic respiratory system disease, with its global prevalence and mortality rates consistently ranking in the top three. Nearly 90% of patients with chronic obstructive pulmonary disease have not received a clear diagnosis, causing a significant social burden. Our recent research: ① found that the airway microbiota can distinguish key phenotypes of chronic obstructive pulmonary disease, revealing the phenomenon of host inflammation association of the microbiota; ② Clarify the relationship between airway microbiota and the subtype of chronic obstructive pulmonary disease (COPD), discover a new subgroup of COPD based on the characteristics of airway microbiota, and propose a new model of "microbiota inflammation" combined typing; ③ Establish a new method for multi omics analysis, draw a network of association between chronic obstructive pulmonary disease (COPD) microbiota and host, and elucidate the mechanism of microbiota host interaction; ④ Revealing the impact of environmental pollution exposure on respiratory health through respiratory microbiota disorders, and identifying respiratory microbiota risk factors for early onset of chronic obstructive pulmonary disease. The above research provides scientific basis for the use of respiratory microbiome as a new biomarker and potential intervention target for respiratory diseases.
